University of Birmingham

Submucosal diclofenac for acute postoperative pain in third molar surgery

Gorecki, Patricia; Rainsford, Kim D.; Taneja, Pankaj ; Bulsara, Yogesh; Pearson, David ; Saund, Daniel ; Ahmed, Bilal ; Dietrich, Thomas

Document Version
Peer reviewed version

[Link to publication on Research at Birmingham portal](#)

**Journal of
Dental Research**

Submucosal Diclofenac for Acute Postoperative Pain in Third Molar Surgery

Journal:	*Journal of Dental Research*
Manuscript ID	JDR-17-0728.R1
Manuscript Type:	Research Reports
Date Submitted by the Author:	26-Sep-2017
Complete List of Authors:	Gorecki, Patricia; University of Birmingham School of Dentistry, Oral Surgery Rainsford, Kim; Sheffield Hallam University, Biomedical Research Centre Taneja, Pankaj; Birmingham Dental Hospital Bulsara, Yogesh; University of Birmingham School of Dentistry, Oral Surgery Pearson, David; Birmingham Dental Hospital Saund, Daniel; Birmingham Dental Hospital, Oral Surgery Ahmed, Bilal; Birmingham Dental Hospital Dietrich, Thomas; University of Birmingham School of Dentistry, Oral Surgery
Keywords:	Anesthesia, Clinical studies/trials, Oral & Maxillofacial Surgery, Pain, Pharmacology
Abstract:	Diclofenac sodium is a widely used non-steroidal anti-inflammatory drug (NSAID) for relief of inflammatory pain. A recent formulation combines this drug with hydroxypropyl-β-cyclodextrin (HPβCD) to improve its solubility and to enable subcutaneous administration. Previous studies confirmed the efficacy of this combination. This study's aim was to evaluate the efficacy, safety and local tolerability of diclofenac HPβCD administered as a local submucosal injection prior to lower third molar surgery. We conducted a prospective, randomised, double-blind, placebo-controlled, parallel-group phase II single centre study. Seventy-five patients requiring mandibular third molar surgery were randomised into one of five groups: 5mg/1mL diclofenac HPβCD, 12.5mg/1mL diclofenac HPβCD, 25mg/1mL diclofenac HPβCD, 50mg/1mL diclofenac HPβCD or 1mL placebo. The respective study drug was injected into the mucosal tissue surrounding the surgical site prior to surgery following achievement of local anaesthesia. The primary outcome measure was the Area Under the Curve (AUC) of cumulative pain scores over the time from end of surgery to 6 hours post-surgery. This demonstrated a global treatment effect between the active groups and placebo, hence confirming the study drug's efficacy (p=0.0126). Secondary outcome measures included the time until onset of pain and the time until patients required rescue medication, both showing statistical significance of the study drug compared to placebo (p<0.0161 and p<0.0001, respectively). The time until rescue medication ranged between 7.8hrs (for 25mg/1mL diclofenac HPβCD) and 16hrs (for 50mg/1mL diclofenac

HPβCD). Interestingly, the 5mg/1mL solution appeared superior to the 12.5mg/1mL and 25mg/1mL (time until rescue medication = 12.44hrs). A total of 14% of patients experienced minor Adverse Drug Reactions (ADRs) of which two cases demonstrated flap necrosis. These resolved without further intervention. The study results overall indicate efficacy, safety and relative tolerability of diclofenac HPβCD used locally as a submucosal injection prior to third molar surgery (ClinicalTrials.gov-Identifier: NCT01706588).

SCHOLARONE™
Manuscripts

Submucosal Diclofenac for Acute Postoperative Pain in Third Molar Surgery: A randomized, controlled clinical trial

[1] Patricia Gorecki, Dr. med. dent, [2] Kim D. Rainsford, PhD, [1] Pankaj Taneja, [1] Yogesh Bulsara, [1] David Pearson, [1] Daniel Saund, [1] Bilal Ahmed, [1] Thomas Dietrich, Dr. med. dent.

[1] The School of Dentistry, Institute of Clinical Sciences, University of Birmingham, Birmingham Dental Hospital Edgbaston, B5 7EG, UK

[2] Biomedical Research Centre, Sheffield Hallam University, Sheffield, S1 1WB, UK

Address for Correspondence:

Professor Thomas Dietrich,

The School of Dentistry,

Birmingham Dental Hospital,

Institute of Clinical Sciences,

University of Birmingham,

5 Mill Pool Way,

Edgbaston, Birmingham, B5 7EG, England, UK

Tel: 0044-1214665495

Email: t.dietrich@bham.ac.uk

1

No conflict of interest.

Clinical Trial Registration: ClinicalTrials.gov identifier NCT01706588

Abstract word count: 296

Manuscript word count (Introduction – Discussion): 3198

Total word count (Abstract – Acknowledgements): 3584

Number of tables: 2

Number of figures: 3

Number of references: 38

Short (running) Title: SC hydroxypropyl-β-cyclodextrin – Diclofenac Na

Keywords: diclofenac sodium, hydroxypropyl-β-cyclodextrin, dental surgery, dental pain, submucosal injection, NSAIDs

2

Abstract

Diclofenac sodium is a widely used non-steroidal anti-inflammatory drug (NSAID) for relief of inflammatory pain. A recent formulation combines this drug with hydroxypropyl-β-cyclodextrin (HPβCD) to improve its solubility and to enable subcutaneous administration. Previous studies confirmed the efficacy of this combination. This study's aim was to evaluate the efficacy, safety and local tolerability of diclofenac HPβCD administered as a local submucosal injection prior to lower third molar surgery. We conducted a prospective, randomised, double-blind, placebo-controlled, parallel-group phase II single centre study. Seventy-five patients requiring mandibular third molar surgery were randomised into one of five groups: 5mg/1mL diclofenac HPβCD, 12.5mg/1mL diclofenac HPβCD, 25mg/1mL diclofenac HPβCD, 50mg/1mL diclofenac HPβCD or 1mL placebo. The respective study drug was injected into the mucosal tissue surrounding the surgical site prior to surgery following achievement of local anaesthesia. The primary outcome measure was the Area Under the Curve (AUC) of cumulative pain scores over the time from end of surgery to 6 hours post-surgery. This demonstrated a global treatment effect between the active groups and placebo, hence confirming the study drug's efficacy (p=0.0126). Secondary outcome measures included the time until onset of pain and the time until patients required rescue medication, both showing statistical significance of the study drug compared to placebo (p<0.0161 and p<0.0001, respectively). The time until rescue medication ranged between 7.8hrs (for 25mg/1mL diclofenac HPβCD) and 16hrs (for 50mg/1mL diclofenac HPβCD). Interestingly, the 5mg/1mL solution appeared superior to the 12.5mg/1mL and 25mg/1mL (time until rescue medication = 12.44hrs). A total of 14% of patients experienced minor Adverse Drug Reactions (ADRs) of which two cases demonstrated flap necrosis. These

3

resolved without further intervention. The study results overall indicate efficacy,

safety and relative tolerability of diclofenac HPβCD used locally as a submucosal

injection prior to third molar surgery (ClinicalTrials.gov-Identifier: NCT01706588).

4

Introduction

Diclofenac is a well-established non-selective non-steroidal anti-inflammatory drug (NSAID). Due to its anti-inflammatory, anti-pyretic and analgesic properties it is commonly used to treat acute/chronic pain, and inflammation (Barden et al. 2004; Blair and Plosker 2015; Gan 2010; Hersh et al. 2004; Moore 2007; Moore et al. 2015c; Sengupta et al. 1985). Diclofenac sodium's acidic form is poorly soluble (Sengupta et al. 1985) and therefore available as the sodium salt with pharmaceutically acceptable solvents, e.g.propylene glycol and benzyl alcohol to enable intramuscular (IM) and intravenous administration. Recent formulations use the complexing agent hydroxypropyl-β-cyclodextrin (HPβCD), serving as a solubility enhancer and facilitating smaller volumes for subcutaneous (SC) or submucosal application (Albers and Muller 1995; Blair and Plosker 2015), with previous studies confirming its successful and safe SC use (Chiarello et al. 2015; Dietrich et al. 2014; Zeitlinger et al. 2012).

Local submucosal drug injection is well-established with local anaesthetics, but otherwise rarely used. The submucosal injection of dexamethasone (Chen et al. 2017; Moraschini et al. 2016; Saravanan et al. 2016) in the context of lower third molar (LM3) surgery is a notable exception. Submucosal injection of analgesics has been described with ketorolac in endodontic pain management (Penniston and Hargreaves 1996) and tramadol in LM3 surgery (Ceccheti et al. 2014), combining the advantages of parenteral drug administration with an administration route that every dentist will be comfortable with. Both studies evaluated standard analgesic doses of the respective analgesic drug.

However, we hypothesized that local submucosal injection of diclofenac may achieve analgesia at markedly lower than standard analgesic doses, taking advantage of high

5

concentrations locally at the site of tissue insult. This would be an attractive novel concept, potentially achieving analgesia while minimising side-effects. We planned the present study to meet two objectives; (i) to provide proof-of-principle or otherwise of low dose local analgesia and (ii) to evaluate the potential for submucosal diclofenac HPβCD as a pre-emptive analgesic in LM3 surgery, as this would have immediate clinical application, if effective. The aim of the present study was therefore to investigate the efficacy, local tolerability and safety of pre-emptive submucosal injection of different diclofenac HPβCD doses for postoperative analgesia in a phase-II, proof-of-principle study.

Materials and Methods

Study design

This investigator-initiated trial was a prospective, randomised, double-blind, placebo-controlled, parallel-group, phase-II single-centre study, conducted at The School of Dentistry, University of Birmingham and the Birmingham Dental Hospital, Birmingham, UK. Ethical approval was obtained by the Ethics Committee, Office for Research Ethics Committees Northern Ireland. The trial adhered to the Declaration of Helsinki and the International Conference on Harmonisation (IHC) consolidated Guideline on Good Clinical Practice (GCP).

Patients (aged 18 to 65), referred for the surgical removal of a LM3 under local anaesthesia (LA) requiring osteotomy, were eligible to participate (please see online appendix for full list of inclusion/exclusion criteria). Written informed consent had to be provided to be enrolled.

Intervention

Patients received one of four diclofenac HPβCD (Akis®/Dicloin®, IBSA, Lugano, Switzerland) doses (50mg/1mL, 25mg/1mL, 12.5mg/1mL or 5mg/1mL), or 1ml placebo (sterile water, Appendix Figure 1).

Randomisation, allocation concealment and blinding

The investigational drug and preparation instructions were supplied packed in identical, sealed boxes, numbered sequentially according to a pre-defined, computer-generated randomisation list in blocks of 10 (i.e., with two kits for each treatment dose level). No stratification was used. None of the investigators were aware of the randomisation method for the duration of the study to minimise risk of selection bias.

7

Following confirmation of all eligibility criteria on the surgery day, the next available randomisation number was allocated to the patient. A single trained study-team member (PT), not involved in any other study procedure, opened the corresponding study medication pack and prepared the syringe for injection in a separate room. Placebo, 25mg and 50mg ampoules appeared identical; however, 5mg and 12.5mg formulations were prepared by diluting a 25mg ampoule with water for injection, with relevant instructions being contained in the medication pack. All 1mL syringes were delivered unmarked to the surgeon for administration. Neither the surgeon nor any other study-team member was made aware of its contents.

Surgery and follow-up

Experienced Oral Surgeons performed the LM3 removal within 30 days of the screening visit using a standard surgical protocol (see Appendix). The study medication was injected in three sites buccal to the LM3 (approximately equal distance apart, about 0.33mL per site), following achievement of LA.

During the postoperative 6-hour-observational period at the investigational site pain measurements (using a 0-100mm Visual Analogue Scale (VAS)), the amount of rescue medication (RM) consumed (i.e.500mg paracetamol tablets) and surgical site appearance regarding bleeding, local irritancy/tolerability were recorded. Patients were then discharged and continued to make hourly pain ratings and recorded any RM intake in a postoperative diary for a further 6 hours. From the day after surgery, patients recorded the RM amount and an overall pain rating for each postoperative day (using a 0-100mm VAS) on a daily basis for one week.

Patients returned for two follow-up visits (=day 2 and 7 post-surgery) to assess postoperative extra-oral swelling, trismus and wound healing and verify RM consumption.

Where required, extractions of any additional teeth were performed outside the trial.

Baseline/Surgical Data

A number of demographic, lifestyle and surgical data were collected at the respective study visits (see Appendix).

Outcome measures and statistical analyses

The primary endpoint was the Area Under the Curve (AUC) of pain scores over time (assessed using 0-100mm VAS), from end of surgery until 6 hours post-surgery compared between treatment groups.

Assuming a standard deviation of 20mm and a mean difference (over the 6 hours) between groups of 25mm, a sample size of 12 patients per group would be required for two-by-two comparisons at $\alpha=0.05$ and 80% power. Therefore, 15 patients per group were considered sufficient to preliminarily investigate the treatment's efficacy.

The following secondary endpoints were evaluated (see Appendix for further details):

- AUC of pain scores over the 12-hour-observation period post-surgery
- Time to onset of pain and time to RM
- Extra-oral swelling and trismus 6 hours post-surgery, on day 2 and 7
- Peak-Pain-Intensity and RM consumption
- Cumulative proportions of patients using RM over the 6-hour-in-clinic-observation period

9

- Adverse events

Prespecified analysis plan

Baseline/surgical characteristics were summarised by treatment group to evaluate whether the groups were balanced at randomisation, with mean/standard deviation used for continuous measures and number/percentage for categorical variables.

Baseline characteristics were compared between the study groups using ANOVA models and Fisher's exact test.

Missing VAS pain scores or values after RM for the timed assessments in the 12h-postoperative period were replaced by using a linear interpolation method. For this purpose, the linear trend between the last two valid VAS scores was used to replace the missing value. Patients' pain ratings on postoperative days were not replaced, irrespective of timing of RM intake.

Three populations were considered for analysis, Intention-To-Treat (ITT), Per-Protocol (PP) and Safety Population (see Appendix for details).

The primary endpoint analysis was conducted using both ITT and PP. Additionally to the unadjusted analyses, a multivariable analysis was performed, adjusting for BMI, amount of bone removal and gender in the ANOVA model. Post-hoc testing for pairwise comparisons between active and placebo groups did not adjust for multiple comparisons.

All other endpoints were analysed using the ITT principle. Safety variables (AEs) were assessed using the Safety Population.

Treatment effect estimates were reported with 95% confidence intervals and statistical tests performed at $\alpha=0.05$.

Results

We screened 80 patients between January and May 2013. Out of the 75 randomised

patients, 15 each were allocated to the 5mg, 12.5mg and 25mg diclofenac HPβCD

group, 14 to the 50mg HPβCD group and 16 to placebo (Appendix Figure 1).

Protocol violations

Two patients were excluded from the PP population due to major protocol violations,

i.e.missing or delayed (=delay ≥15mins from scheduled time) pain measurements,

which occurred in the 6-hour post-surgery period.

Demographic/surgical characteristics

Demographic and surgical characteristics were overall well-balanced between study

groups (Table 1).

Efficacy variables

Primary outcome measure

We found a global treatment effect in both ITT and PP populations (p=0.0126 and

p=0.0057, respectively). In contrast, no statistically significant differences were found

between the active study arms (Table 2, Figure 1).

Adjustment for sex, BMI and amount of bone removal as covariates, also confirmed a

global treatment effect between active and placebo arms (p=0.0188). Likewise, no

statistically significant difference was noted between the diclofenac groups. Also,

none of the covariates exerted an influence on the primary variable.

Secondary outcome measures

11

The AUC of VAS scores over the 12-hour postoperative period revealed similar results to the 6-hour postoperative period with the Least Square Means (LSMs) being lower in the active groups compared with placebo (p=0.0471). A global treatment effect was seen between the diclofenac groups and placebo apart from the comparison between 25mg diclofenac HPβCD and placebo (p=0.1093). No statistically significant differences were observed between active treatment groups (Table 2, Figure 1).

The active groups exhibited longer time until pain onset compared to placebo (p=0.0161 for overall treatment effect). Again, no statistical differences were found between diclofenac groups (Table 2, Figure 2).

The time until first RM was significantly shorter in the placebo group compared to the active treatment groups, demonstrating again a global treatment effect (p<0.0001). Between the active groups no statistically significant differences were observed (Table 2, Figure 3).

The cumulative proportion of patients taking RM over the 6-hour-period post-surgery was higher in placebo compared with the diclofenac groups (p=0.0483) (Table 2).

Peak-Pain-Intensity analysis showed no global treatment effect (p=0.8595). Likewise, evaluation of trismus revealed no statistically significant differences between active groups and placebo, measured at 6 hours (p=0.1691), 2 days (p=0.5428) and 7 days (p=0.6260) post-surgery. Similar findings were observed for the extra-oral swelling measured at 6 hours (p=0.3855) and 2 days (p=0.5933). However, a global treatment effect was noted at 7 days after surgery, with a small but statistically significant difference in favour of the diclofenac groups compared to placebo (p=0.0214) (Table 2).

Safety/tolerability

AEs and Adverse Drug Reactions <mark>(ADRs=AEs occurring after injection of study drug and with causal relationship to study drug, as judged by investigator)</mark> were monitored throughout the study period. The causal relationship between AEs and the study drug was assessed at the time when the event occurred.

The number of patients experiencing at least one AE was 8 (=53.3%) in the 5mg Diclofenac group, 9 (=60%) in the 12.5mg, 8 (=53.3%) in the 25mg and 5 (=35.7%) in the 50mg group. Six (=37.5%) AEs were reported amongst placebo patients (Appendix Table 1). The number of participants experiencing AEs did not differ significantly between groups. The most frequently occurring AEs were headache, vomiting and facial swelling (Appendix Table 2).

The percentage of ADRs was 13.3% in both the 5mg and 12.5mg Diclofenac group, 33.3% in the 25mg and 14.3% in the 50mg group. Placebo group patients did not report any ADRs (Appendix Table 1). The most frequent ADRs were injection site reactions, i.e.pain or swelling (Appendix Table 3). Two cases of flap necrosis were observed during the post-operative observation period. One mild ulceration arose in the 25mg group at the 2-day review appointment and one moderate ulceration was observed in the 50mg group at the 7-day review appointment (Appendix Figure 2 and 3). These resolved spontaneously, without requiring any countermeasures. The number of ADRs did not differ significantly between groups.

No Serious Adverse Events (SAEs) were recorded.

Discussion

This trial aimed at evaluating the safety, tolerability and efficacy of varying doses of diclofenac HPβCD (5mg, 12.5mg, 25mg, 50mg) injected locally prior to LM3 surgery.

The choice of diclofenac sodium as an anti-inflammatory analgesic for relief of mild-moderate dental pain is supported by (a)extensive studies reported from the Cochrane database (Barden et al. 2004; Moore 2007; Moore et al. 2015b; Moore et al. 2015c) showing this drug's effectiveness in dental pain with low AE incidence encountered with other NSAIDs and analgesics (Gan 2010; Moore et al. 2015a); (b)rapid absorption from oral/parenteral preparations and other favourable pharmacokinetic properties (Sengupta et al. 1985) as well as its ability to accumulate into the cerebrospinal fluid and pain inhibition in the central nervous system (Bjorkman and Elam 1993; Kokki et al. 2008); and (c)its novel mechanism of analgesia involving selective effects on ion channels (Duan et al. 2012; Gwanyanya et al. 2012) quite separate from its well-known actions as a potent inhibitor of cyclo-oxygenases and inflammatory-pain-producing prostaglandins (Gan 2010; Rainsford 2015), lipoxygenases (Gan 2010), nitric oxide-cGMP anti-nociceptive pathway activation and NMDA-receptor analgesia (Gan 2010). Some of these actions delineate diclofenac from other NSAIDs and may contribute to its potent effects as an acute pain-relieving drug.

All four drug dose levels produced significantly superior effects compared with placebo in preventing pain during the 6-hour post-surgical observation period in terms of pain intensity levels, time until pain onset and time to first RM intake. The results are consistent with findings from previous studies showing the efficacy of the

14

parenterally administered sodium diclofenac HPβCD formulation (Blair and Plosker 2015; Chiarello et al. 2015; Dietrich et al. 2014).

No dose-dependent effects were observed in the four active groups in any of the evaluated endpoints. The lack of dose-dependency could be related to zero-order kinetics that may be apparent with the localised intra-mucosal delivery of high concentrations of the drugs. Zero-order kinetics have been observed with several drugs administered subcutaneously, including those from controlled-release systems (Cho et al. 1982; Hill et al. 2012; Liu et al. 2007; Mei et al. 2010). Interestingly, the 5mg dose demonstrated slightly better analgesic efficacy over the 6- and 12-hour postoperative evaluation period, although this was not significantly different from that observed with the other dose levels. Also, the time until pain onset and RM was longer than in the 12.5mg and 25mg group. The concept of locally/sub-mucosally injected analgesics is a fairly unexplored territory. The local pharmacokinetic profile of submucosal diclofenac HPβCD is not known. Comparing the pharmacodynamic responses involving pain relief in the present and previous studies (Dietrich et al. 2014) with pharmacokinetic data is only possible in relation to the SC administration route of HPβCD diclofenac into the thigh. Thus, previous studies have shown essentially bioequivalence of 75mg/mL of this formulation when given SC with that when given IM and similar to that with diclofenac sodium as Voltaren® given IM (Zeitlinger et al. 2012). The drug is rapidly absorbed with peak concentrations being achieved from SC and IM administration of HPβCD diclofenac at about 1hr, while those from IM diclofenac sodium were evident at 0.45hr suggesting that the HPβCD may act as a moderate slow-release system. The peak diclofenac concentrations from HPβCD diclofenac are slightly higher following IM compared with both SC administered drugs (Zeitlinger et al. 2012). Overall, however, both formulations

15

achieve similar absorption when administered as the sodium salt or the HPβCD formulation. The volumes of distribution, median residence time and elimination half-life are comparable among the formulations and suggest that the drug is rapidly distributed and eliminated from both formulations. Therefore, an alternative explanation may be that in the context of the dental pain impaction model, a low dose of 5mg is as efficacious as the higher doses. However, topically applied solutions (e.g.Voltaren®) demonstrate a 10x delayed maximal plasma concentration (Altman et al. 2015), and if submucosal application showed a similarly delayed effect the here observed findings could be explained in this way. Furthermore, the vasoconstrictor in the LA, administered immediately before the submucosal diclofenac injection, may also have resulted in a delay of systemic distribution of the drug. Hence, the analgesic effects of submucosal diclofenac observed in the present study could be attributable to local or systemic drug effects, or a combination of both.

We found no evidence for submucosal HPβCD diclofenac injection to have meaningful efficacy as a pre-emptive analgesic (i.e., having analgesic efficacy beyond 5.5 half-lives), as there were no clinically important differences in terms of analgesic consumption or pain levels over the postoperative week (data not shown).

We evaluated the submucosal HPβCD diclofenac's efficacy in a modified (pre-emptive) dental pain impaction model for several reasons. Firstly, we were interested in evaluating an approach that would be suitable for use in clinical practice, as LM3 surgery is usually provided as an outpatient procedure and patients would not be able to inject themselves intra-orally postoperatively. Secondly, previous studies have shown that SC injections may cause some pain/discomfort, which would be minimised with a pre-emptive approach as it allowed submucosal injection following LA.

16

The main reported ADRs were injection site reactions, i.e.pain or swelling, reported in 14.6% of active group patients, which concurs with previous evaluations (Blair and Plosker 2015; Dietrich et al. 2014); although this was somewhat surprising given that the injection was given following LA. Previous studies have shown that there were no serious adverse reactions following SC administration of sodium diclofenac HPβCD at three dose levels of 25, 50 and 75mg/mL (Dietrich et al. 2014; Zeitlinger et al. 2012). Furthermore, Salomone et al.(Salomone et al. 2014) have shown that there are few subjects that showed local reactions to 50mg sodium diclofenac HPβCD at the injection sites in the abdomen, gluteus and quadriceps muscles, with all local reactions being mild-moderate and disappearing by 10mins (i.e.hardening) or 30mins (i.e.swelling and redness).

In the present study, a flap necrosis was observed in two subjects, one in the 25mg and one in the 50mg group (Appendix Figures 2/3). These were highly unusual and not observed previously by the investigators in LM3 surgery. Both resolved without further interventions and without any sequelae. Among the rare adverse skin reactions that have been reported being associated with parenteral injection of diclofenac (Dadaci et al. 2015; Kilic et al. 2014; Nischal et al. 2009) and other drugs (Seremet et al. 2015), antibiotics (Alkan Bozkaya et al. 2016) and vaccines (Rygnestad and Kvam 1995; Stefano et al. 2017; Wronecki and Czernik 1981) is the Nicolau syndrome (Livedoid dermatis or *Embolia cutis medicamentosa*). This was first reported in 1924 by Freudenthal (James et al. 2015; Kilic et al. 2014; Nischal et al. 2009) and is a rare iatrogenic condition characterised by an immediate erythematous skin reaction following injection or ischaemic reaction (pallor) sometimes with a reticular pattern leading to necrosis of the skin and underlying tissue which can be severe and lead to disfigured scarring (James et al. 2015). We believe that the two occurrences of flap

17

necrosis could be unusual mucosal manifestations of Nicolau syndrome. Although previous reports on Nicolau syndrome have implicated diclofenac itself, we cannot rule out HPβCD as a possible cause.

The results of the present study have to be cautiously interpreted due to the limited sample size of this phase-II study, which unsurprisingly resulted in some chance imbalances between groups in terms of patient and surgical characteristics. Thus, confounding by these and other unmeasured factors has to be considered.

Overall, this study indicates efficacy, safety and relative tolerability of diclofenac HPβCD as a local submucosal analgesic. The study provides evidence in support of the novel concept of low-dose local analgesia for the first time. Further studies should include investigation of the study drug's local pharmacokinetics, and larger phase-III trials are required to confirm efficacy and safety of low-dose submucosal analgesia for acute pain management.

18

Authors' contributions

TD designed research. TD, PT, YB, DP, DS and BA conducted research. PG, KR and

TD wrote the paper. TD had primary responsibility for final content.

All authors read and approved the final manuscript.

Acknowledgements

19

References

Albers E, Muller BW. 1995. Cyclodextrin derivatives in pharmaceutics. Crit Rev Ther Drug Carrier Syst. 12(4):311-337.

Alkan Bozkaya T, Demirel G, Ormeci T, Al S, Cakar E, Tastekin A, Turkoglu H. 2016. Anticoagulant and vasodilator therapy for nicolau syndrome following intramuscular benzathine penicillin injection in a 4 year old boy. Arch Argent Pediatr. 114(3):e184-186.

Altman R, Bosch B, Brune K, Patrignani P, Young C. 2015. Advances in nsaid development: Evolution of diclofenac products using pharmaceutical technology. Drugs. 75(8):859-877.

Barden J, Edwards J, Moore RA, McQuay HJ. 2004. Single dose oral diclofenac for postoperative pain. Cochrane Database Syst Rev. (2):CD004768.

Bjorkman R, Elam M. 1993. Diclofenac evaluated in a human experimental model of central pain. Pain. 54(2):197-202.

Blair HA, Plosker GL. 2015. Diclofenac sodium injection (akis((r)), dicloin ((r))): A review of its use in the management of pain. Clin Drug Investig. 35(6):397-404.

Ceccheti MM, Negrato GV, Peres MP, Deboni MC, Naclerio-Homem Mda G. 2014. Analgesic and adjuvant anesthetic effect of submucosal tramadol after mandibular third molar surgery. Oral Surg Oral Med Oral Pathol Oral Radiol. 117(3):e249-254.

Chen Q, Chen J, Hu B, Feng G, Song J. 2017. Submucosal injection of dexamethasone reduces postoperative discomfort after third-molar extraction: A systematic review and meta-analysis. J Am Dent Assoc. 148(2):81-91.

Chiarello E, Bernasconi S, Gugliotta B, Giannini S. 2015. Subcutaneous injection of diclofenac for the treatment of pain following minor orthopedic surgery (direct study): A randomized trial. Pain Pract. 15(1):31-39.

Cho MJ, Kurtz RR, Lewis C, Machkovech SM, Houser DJ. 1982. Metronidazole phosphate--a water-soluble prodrug for parenteral solutions of metronidazole. J Pharm Sci. 71(4):410-414.

Dadaci M, Altuntas Z, Ince B, Bilgen F, Tufekci O, Poyraz N. 2015. Nicolau syndrome after intramuscular injection of non-steroidal anti-inflammatory drugs (nsaid). Bosn J Basic Med Sci. 15(1):57-60.

Dietrich T, Leeson R, Gugliotta B, Petersen B. 2014. Efficacy and safety of low dose subcutaneous diclofenac in the management of acute pain: A randomized double-blind trial. Pain Pract. 14(4):315-323.

Duan KZ, Xu Q, Zhang XM, Zhao ZQ, Mei YA, Zhang YQ. 2012. Targeting a-type k(+) channels in primary sensory neurons for bone cancer pain in a rat model. Pain. 153(3):562-574.

Gan TJ. 2010. Diclofenac: An update on its mechanism of action and safety profile. Curr Med Res Opin. 26(7):1715-1731.

Gwanyanya A, Macianskiene R, Mubagwa K. 2012. Insights into the effects of diclofenac and other non-steroidal anti-inflammatory agents on ion channels. J Pharm Pharmacol. 64(10):1359-1375.

20

Hersh EV, Levin LM, Adamson D, Christensen S, Kiersch TA, Noveck R, Watson G, 2nd, Lyon JA. 2004. Dose-ranging analgesic study of prosorb diclofenac potassium in postsurgical dental pain. Clin Ther. 26(8):1215-1227.

Hill A, Geissler S, Weigandt M, Mader K. 2012. Controlled delivery of nanosuspensions from osmotic pumps: Zero order and non-zero order kinetics. J Control Release. 158(3):403-412.

James WD, Berger TG, Elston DM. 2015. Andrew's diseases of the skin. Clinical dermatology. WB Saunders.

Kilic I, Kaya F, Ozdemir AT, Demirel T, Celik I. 2014. Nicolau syndrome due to diclofenac sodium (voltaren(r)) injection: A case report. J Med Case Rep. 8:404.

Kokki H, Kumpulainen E, Laisalmi M, Savolainen J, Rautio J, Lehtonen M. 2008. Diclofenac readily penetrates the cerebrospinal fluid in children. Br J Clin Pharmacol. 65(6):879-884.

Liu Y, Lu WL, Wang JC, Zhang X, Zhang H, Wang XQ, Zhou TY, Zhang Q. 2007. Controlled delivery of recombinant hirudin based on thermo-sensitive pluronic f127 hydrogel for subcutaneous administration: In vitro and in vivo characterization. J Control Release. 117(3):387-395.

Mei L, Bao J, Tang L, Zhang C, Wang H, Sun L, Ma G, Huang L, Yang J, Zhang L et al. 2010. A novel mifepristone-loaded implant for long-term treatment of endometriosis: In vitro and in vivo studies. Eur J Pharm Sci. 39(5):421-427.

Moore N. 2007. Diclofenac potassium 12.5mg tablets for mild to moderate pain and fever: A review of its pharmacology, clinical efficacy and safety. Clin Drug Investig. 27(3):163-195.

Moore RA, Derry S, Aldington D, Wiffen PJ. 2015a. Adverse events associated with single dose oral analgesics for acute postoperative pain in adults - an overview of cochrane reviews. Cochrane Database Syst Rev. (10):CD011407.

Moore RA, Derry S, Aldington D, Wiffen PJ. 2015b. Single dose oral analgesics for acute postoperative pain in adults - an overview of cochrane reviews. Cochrane Database Syst Rev. (9):CD008659.

Moore RA, Wiffen PJ, Derry S, Maguire T, Roy YM, Tyrrell L. 2015c. Non-prescription (otc) oral analgesics for acute pain - an overview of cochrane reviews. Cochrane Database Syst Rev. (11):CD010794.

Moraschini V, Hidalgo R, Porto Barboza E. 2016. Effect of submucosal injection of dexamethasone after third molar surgery: A meta-analysis of randomized controlled trials. Int J Oral Maxillofac Surg. 45(2):232-240.

Nischal K, Basavaraj H, Swaroop M, Agrawal D, Sathyanarayana B, Umashankar N. 2009. Nicolau syndrome: An iatrogenic cutaneous necrosis. J Cutan Aesthet Surg. 2(2):92-95.

Penniston SG, Hargreaves KM. 1996. Evaluation of periapical injection of ketorolac for management of endodontic pain. J Endod. 22(2):55-59.

Rainsford K. 2015. Pharmacology and toxicology of ibuprofen. In: Rainsford K, editor. Ibuprofen: Discovery, development and therapeutics. Wiley-Blackwell. p. 132-236.

Rygnestad T, Kvam AM. 1995. Streptococcal myositis and tissue necrosis with intramuscular administration of diclofenac (voltaren). Acta Anaesthesiol Scand. 39(8):1128-1130.

21

Salomone S, Piazza C, Vitale DC, Cardi F, Gugliotta B, Drago F. 2014. Pharmacokinetics of a new subcutaneous diclofenac formulation administered to three body sites: Quadriceps, gluteus, and abdomen. Int J Clin Pharmacol Ther. 52(2):129-134.

Saravanan K, Kannan R, John RR, Nantha Kumar C. 2016. A single pre operative dose of sub mucosal dexamethasone is effective in improving post operative quality of life in the surgical management of impacted third molars: A comparative randomised prospective study. J Maxillofac Oral Surg. 15(1):67-71.

Sengupta C, Aféche P, Meyer-Brunot HG, Rensing U. 1985. Diclofenac sodium. In: Rainsford K, editor. Anti-inflammatory and anti-rheumatic drugs volume ii: Newer anti-inflammatory drugs. CRC Press. p. 49-63.

Seremet S, Turan E, Erdemir AT. 2015. Nicolau syndrome following intramuscular injection of oxytocin in pregnant women: Report of two cases. Dermatol Online J. 21(8).

Stefano PC, Garello M, Nolte MF, Lamy P, Giglio N, Castellano V, Gentile A. 2017. [nicolau syndrome induced by intramuscular injection of a hexavalent vaccine in a 6-month-old girl]. Arch Argent Pediatr. 115(1):e13-e16.

Wronecki K, Czernik J. 1981. [the nicolau syndrome in children (author's transl)]. Z Kinderchir. 32(4):367-370.

Zeitlinger M, Rusca A, Oraha AZ, Gugliotta B, Muller M, Ducharme MP. 2012. Pharmacokinetics of a new diclofenac sodium formulation developed for subcutaneous and intramuscular administration. Int J Clin Pharmacol Ther. 50(6):383-390.

22

Figure legends

Figure 1 – Pain intensity over time

Pain intensity of the respective study groups from end of surgery until 12 hours post-

surgery

VAS = Visual Analogue Scale

Figure 2 – Time to pain onset

Kaplan Meier survival curve demonstrating the time until onset of pain following

surgery in the respective study groups

Figure 3 – Time to first rescue medication

Kaplan Meier survival curve illustrating the time until the first rescue medication was

consumed postoperatively in the respective study groups

23

Table 1 – Baseline demographic and surgical characteristics; Continuous variables are presented as mean (SD)[c].

	5mg (n=15)	12.5mg (n=15)	25mg (n=15)	50mg (n=14)	Placebo (n=16)
Age (years)	28.33 (7.32)	27.73 (9.35)	29.73 (9.00)	27.36 (4.52)	29.81 (9.54)
Male (%)	40	60	20	43	25
BMI[a]	27.46 (6.50)	24.56 (3.98)	24.11 (4.10)	27.05 (6.43)	24.47 (4.26)
Ethnicity (%)					
Caucasian	53	47	60	93	50
Black	20	20	7	0	6
Asian	27	33	26	7	31
Other	0	0	7	0	13
Preoperative LA[b] **dose (ml)**	5.78 (0.98)	5.72 (1.04)	5.29 (1.21)	5.67 (1.22)	5.70 (1.08)
Supplemental LA (%)	7	7	27	0	6
Bone removal (%)					
Minor	33	33	40	50	44
Moderate	60	47	53	43	44
Severe	7	20	7	7	12
Duration of surgery (mins)	12.93 (5.85)	14.20 (6.74)	10.07 (5.11)	11.64 (6.48)	10.81 (5.11)
Tooth sectioning (%)	67	67	40	57	50
Lingual flap (%)	20	40	13	36	38

[a] BMI = Body Mass Index

[b] LA = Local anaesthetic

[c] SD = Standard Deviation

Table 2 – Primary and secondary outcomes

	5mg (n=15)	12.5mg (n=15)	25mg (n=15)	50mg (n=14)	Placebo (n=16)	p-value$
VAS[a] pain/ AUC[b] 0-6hrs (LSMs[c], ITT[d] population), mean (SD[e])	6843 (6259)	8833 (6331)	9998 (8080)	7290 (6509)	15539 (9280)	0.0126
p-value #	*0.0017*	*0.0144*	*0.0417*	*0.0034*		
VAS[a] pain/ AUC[b] 0-6hrs (LSMs[c], ITT[d] population, multivariable ANOVA*), adjusted mean	6978	9985	10112	7733	15582	0.0188
p-value #	*0.0020*	*0.0394*	*0.0388*	*0.0049*		
VAS pain / AUC 0-6hrs (LSMs, PP[f] population), mean (SD)	5836 (5079)	8833 (6331)	10339 (8273)	7290 (6509)	15539 (9280)	0.0057
p-value #	*0.0005*	*0.0129*	*0.0559*	*0.0029*		

VAS pain/ AUC 0-12hrs (LSMs, ITT population), mean (SD)	22848 (19947)	29481 (17573)	32197 (20729)	25770 (20104)	43890 (21606)	0.0471
p-value #	*0.0047*	*0.0495*	*0.1093*	*0.0160*		
Time to pain onset (hrs), mean (SD)	5.88 (5.86)	4.53 (5.69)	2.88 (2.51)	9.69 (18.90)	1.91 (1.07)	0.0161
Time to first rese medication (hr, mean (SD)	12.44 (10.24)	9.03 (9.08)	7.81 (8.46)	16.05 (18.81)	2.63 (0.53)	<0.0001
Number of patients using rescue medication at 0-6hrs (%)	40	53	73	50	88	0.0483
VAS Peak Pain Intensity, mean (SD)	33.20 (21.24)	36.20 (14.73)	33.53 (16.58)	35.43 (21.54)	41.06 (30.81)	0.8595

Interincisal distance, day 2 (mm), mean (SD)	24.00 (6.89)	28.00 (6.78)	26.80 (9.86)	28.29 (6.76)	26.69 (8.95)	0.5428
Interincisal distance, day 7 (mm), mean (SD)	32.20 (7.16)	33.33 (7.98)	29.47 (8.74)	31.86 (6.40)	35.00 (8.69)	0.6260
Swelling, day 2 (cm), mean (SD)	15.18 (0.95)	15.43 (0.73)	15.09 (0.86)	15.61 (0.95)	15.07 (0.87)	0.5933
Swelling day 7 (cm), mean (SD)	14.92 (1.07)	15.29 (0.82)	14.93 (0.91)	15.47 (0.90)	14.87 (0.83)	0.0214

Continuous variables are presented as mean (SD).

The primary outcome variable (VAS score AUC 0-6hrs post-surgery) was evaluated in the ITT and PP population.

Interincisal distance was measured in mm and represents the distance between left upper and lower incisor at maximal mouth opening.

Swelling represents the tragus to chin distance in cm.

P-value for pairwise comparison between active group and placebo

$ global p-value for treatment effect (ANOVA)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

* Multivariate ANOVA included Body Mass Index (BMI), gender and amount of bone removal as covariates

[a] VAS = Visual Analogue Scale

[b] AUC = Area Under the Curve

[c] LSMs = Least Square Means

[d] ITT = Intention To Treat

[e] SD = Standard Deviation

[f] PP = Per Protocol

Figure 1 – Pain intensity over time

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Figure 2 – Time to pain onset

Figure 3 – Time until first rescue medication

Submucosal Diclofenac for Acute Postoperative Pain in Third Molar Surgery: A randomized

controlled clinical trial

Patricia Gorecki, Kim D. Rainsford, Pankaj Taneja, Yogesh Bulsara, David Pearson, Daniel

Saund, Bilal Ahmed, Thomas Dietrich

Methods

Exclusion criteria

Females of childbearing potential were required to have a negative urine pregnancy test at

the inclusion visit and be using an appropriate contraception method throughout the study

period.

The following exclusion criteria applied:

- Patients refusing to give written informed consent or to return for control visits

- Patients enrolled in a clinical trial in the previous 3 months

- Pregnant or breast-feeding women

- Patients with an allergy to diclofenac/other NSAIDs

- Patients on medication that could affect the efficacy and/or safety outcomes

    assessed in this trial, e.g. corticosteroids, other NSAIDs, anticoagulant/antiplatelet

    agents or antimicrobials.

- Patients with a history of gastrointestinal disorders, coagulation disorders,

    hepatic/renal/cardiac impairment, peripheral arterial disease or uncontrolled

    hypertension

- Patients with major psychiatric disorders compromising study participation in the investigator's opinion

- Alcohol or drug abuse in the previous 12 months

Surgery and follow-up

Patients received an appointment for their LM3 removal within 30 days of their screening visit. Lidocaine 2% with 1:80.000 epinephrine (Septodont, Maidstone, Kent, UK) was used for LA (administered as an inferior dental nerve block and buccal infiltration). The maximum allowed dose of 8.8mL included intraoperative supplemental administration, if necessary. Once LA was achieved a 1mL submucosal injection of the study medication was given in three sites (approximately equal distance apart) buccal to the third molar area, with about 0.33mL given per site.

Experienced oral surgeons performed the surgery using a standard surgical procedure. A muco-periosteal envelope or triangular flap was raised according to the surgeon's preference, bone removal and tooth sectioning was performed using a surgical hand-piece and burs as required, the respective tooth was elevated and interrupted sutures were placed to achieve wound closure (Vicryl Rapide®, Ethicon, Johnson & Johnson Medical Ltd., Norderstedt, Germany).

Following surgery patients received standard postoperative instructions and stayed at the investigational site for 6 hours for the assessment of pain (using a 0-100mm Visual Analogue Scale (VAS)), the amount of rescue medication consumed (i.e. 500mg paracetamol tablets) and the appearance of the surgical site regarding bleeding and assessment of the local irritancy and tolerability. After the observational period participants were discharged with a box of paracetamol and a postoperative diary to record their pain levels, analgesic and other

concomitant medication consumption and adverse events (AEs) on a daily basis for one week.

Patients were asked to return for two follow-up visits on day 2 and 7 after surgery (=visits 3 and 4) during which post-surgical extra-oral swelling and trismus, as well as wound healing were assessed and rescue medication consumption was verified.

Baseline/Surgical Data

Demographic and lifestyle data were collected at the screening visit, including age, gender, ethnicity, weight, height and Body Mass Index (BMI). On the day of surgery some surgical measurements were collected, i.e. which LM3 was removed (left/right), whether the tooth was removed completely (yes/no), preoperative LA dose (in mL), supplemental LA dose (in mL), amount of bone removal (minor/moderate/severe), tooth sectioning (yes/no), raising of lingual flap (yes/no) and duration of surgery (in min).

Prespecified analysis plan

- Intention-To-Treat (ITT)= all randomised patients receiving ≥one study medication dose and with ≥one post-baseline efficacy evaluation;

- Per-Protocol (PP)= all ITT population patients without major protocol violation;

- Safety Population= all randomised patients receiving the study intervention.

Outcome measures and statistical analyses

The following secondary endpoints were evaluated:

- AUC of pain scores over the 12-hour-observation period post-surgery (assessed at the end of surgery, at 15mins intervals for the 6-hour-observation period on clinic and hourly for 6 hours after discharge), using an ANOVA model;

- Time to onset of pain (=pain ≥30mm on VAS) and time to RM, using survival analysis;

- Extra-oral swelling (=distance between lower border of tragus and a point in the midline, 3cm below vermilion border of lower lip, marked in removable ink on patient's chin) and trismus (=distance between left upper and lower incisor at maximal opening, assessed using a ruler) 6 hours post-surgery, on day 2 and day 7, using an ANOVA model;

- Peak-Pain-Intensity (=highest pain intensity during the 12-hour-observation period post-surgery) and RM consumption, using an ANOVA model;

- Cumulative proportions of patients using RM over the 6-hour-in-clinic-observation period, using chi-square test;

- AE comparisons (reported as description of event, intensity (mild/moderate/severe), seriousness (serious/non-serious), date of onset/end, expectation (expected/unexpected) and correlation with study treatment (certain/probable/possible/unlikely/not related/not assessable)), using Fisher's exact test.

Results:

Appendix Table 1: AEs and ADRs occurring after injection of study medication (safety population)

Variable	5mg	12.5mg	25mg	50mg	Placebo	Total
	(n=15)	(n=15)	(n=15)	(n=14)	(n=16)	(n=75)
Adverse Events (AEs[a])						
Total number of AEs	23	20	25	9	15	92
Patients with at least one AE, N (%)	8 (53.3%)	9 (60%)	8 (53.3%)	5 (35.7%)	6 (37.5%)	36 (48%)
Adverse Drug reactions (ADRs[b])						
Total number of ADRs	2	3	9	2	0	16
Patients with ADRs, N (%)	2 (13.3%)	2 (13.3%)	5 (33.3%)	2 (14.3%)	0 (0%)	11 (14.6%)

[a] AEs = Adverse Event

[b] ADRs = Adverse Drug Reaction

Supplemental Material, Gorecki et al.

5

Appendix Table 2: AEs classified by PT (=preferred patient term)

AE[a] description	5mg n=15	12.5mg n=15	25mg n=15	50mg n=14	Placebo n=16
Diarrhoea, N (%)	1 (7%)	0	0	0	1 (6%)
Nausea, N (%)	1 (7%)	0	0	1 (7%)	2 (13%)
Vomiting, N (%)	2 (13%)	1 (7%)	2 (13%)	0	1 (6%)
Dizziness, N (%)	0	1 (7%)	1 (7%)	0	0
Headache, N (%)	4 (27%)	1 (7%)	2 (13%)	1 (7%)	2 (13%)
Jaw pain, N (%)	1 (7%)	4 (27%)	0	0	2 (13%)
Injection site pain, N (%)	2 (13%)	2 (13%)	5 (33%)	1 (7%)	0
(Injection site) swelling, N (%)	2 (13%)	0	2 (13%)	0	0
Flap necrosis, N (%)	0	0	1 (7%)	1 (7%)	0
Wound infection, N (%)	1 (7%)	1 (7%)	1 (7%)	0	1 (6%)
Gingival bleeding, N (%)	1 (7%)	0	1 (7%)	0	0

[a] AE = Adverse Event

Supplemental Material, Gorecki et al.   6

Appendix Table 3: ADRs classified by PT (=preferred patient term)

ADR[a] description	5mg n=15	12.5mg n=15	25mg n=15	50mg n=14	Placebo n=16
Flap necrosis, N (%)	0	0	1 (7%)	1 (7%)	0
Injection site pain, N (%)	2 (13%)	2 (13%)	5 (33%)	1 (7%)	0
Injection site swelling, N (%)	0	0	2 (13%)	0	0

[a] ADR = Adverse Drug Reaction

Supplemental Material, Gorecki et al.

7

Supplementary Figure 1: Study Consort Flow Diagram

Eighty patients were screened for eligibility, out of which 75 were randomised and completed

the randomised controlled trial.

Supplementary Figure 2: Partial flap necrosis in the 25mg/1mL HPβCD[1] diclofenac group,

evident at 2-day review.

The patient was completely asymptomatic. The necrosis was present around the margins of

the mucoperiosteal flap. This resolved without further intervention by the 7-day post-

operative review appointment.

[1] HPβCD - hydroxypropyl-β-cyclodextrin

Supplementary Figure 3: Partial flap necrosis in the 50mg/1mL HPβCD dicolfenac group

evident at 7-day review.

The patient was asymptomatic and the necrosis recovered without further intervention

(similar to the necrosis seen in the 25mg/1mL group – see Appendix Figure 2).

[1] HPβCD - hydroxypropyl-β-cyclodextrin

CONSORT 2010 checklist of information to include when reporting a randomised trial*

Section/Topic	Item No	Checklist item	Reported on page No
Title and abstract			
	1a	Identification as a randomised trial in the title	1
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	3, 4
Introduction			
Background and	2a	Scientific background and explanation of rationale	5, 6
objectives	2b	Specific objectives or hypotheses	5, 6
Methods			
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	7
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	N/A
Participants	4a	Eligibility criteria for participants	7, Appendix
	4b	Settings and locations where the data were collected	7
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	7, 8
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed	9, 10
	6b	Any changes to trial outcomes after the trial commenced, with reasons	N/A
Sample size	7a	How sample size was determined	9
	7b	When applicable, explanation of any interim analyses and stopping guidelines	N/A
Randomisation:			
Sequence	8a	Method used to generate the random allocation sequence	7, 8
generation	8b	Type of randomisation; details of any restriction (such as blocking and block size)	7
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	7, 8
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	7, 8
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those	7, 8

CONSORT 2010 checklist

Page 1

		assessing outcomes) and how	
	11b	If relevant, description of the similarity of interventions	8
Statistical methods	12a	Statistical methods used to compare groups for primary and secondary outcomes	9 - 11
	12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses	10
Results			
Participant flow (a diagram is strongly recommended)	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome	12
	13b	For each group, losses and exclusions after randomisation, together with reasons	12
Recruitment	14a	Dates defining the periods of recruitment and follow-up	12
	14b	Why the trial ended or was stopped	N/A
Baseline data	15	A table showing baseline demographic and clinical characteristics for each group	Table 1
Numbers analysed	16	For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups	12
Outcomes and estimation	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)	12, 13, Table 2
	17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended	Table 2
Ancillary analyses	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory	12
Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	14, Suppl. Tables
Discussion			
Limitations	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	16-19
Generalisability	21	Generalisability (external validity, applicability) of the trial findings	15-19
Interpretation	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	15-19
Other information			
Registration	23	Registration number and name of trial registry	2, 4
Protocol	24	Where the full trial protocol can be accessed, if available	N/A
Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	2, 20

*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org.

CONSORT 2010 checklist   *Page 2*